A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

Inclusion Criteria: * Aged at least 18 years * Signed informed consent * Comfirmed diagnosis of HAE with baseline plasma level of functional C1INH activity of less than 50% of normal, and/or proven HAE ,mutation in C1INH gene. Exclusion Criteria: * A history of anaphylaxis or severe allergy (i.e. requiring medication) to food, proteins and/or drugs. * A history of allergic reactions to C1INH products or rabbit protein. * Any reported SAE related to study drug administration (withdrawal criterium) * Elevated IgE against rabbit dander (\>0.35 kU/L; ImmunoCap assay; Phadia) * A diagnosis of acquired C1INH deficiency. * Woman of child bearing potential, pregnancy or breast-feeding * previous treatment within the last 3 months with plasma-derived C1INH * Any clinically significant abnormality in the routine haematology, biochemistry and urinalysis * Any condition or treatment that in the opinion of the investigator might interfere with the evaluation of the study objectives. * Any changes since screening that would exclude subject based on above exclusion criteria.